272 related articles for article (PubMed ID: 9384476)
1. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sweetenham JW; Taghipour G; Milligan D; Blystad AK; Caballero D; Fassas A; Goldstone AH
Bone Marrow Transplant; 1997 Nov; 20(9):745-52. PubMed ID: 9384476
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
5. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[TBL] [Abstract][Full Text] [Related]
7. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen.
Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J
Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724
[TBL] [Abstract][Full Text] [Related]
9. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant.
Arranz R; Tomás JF; Gil-Fernández JJ; Martínez-Chamorro C; Granados E; Alegre A; Figuera A; Vázquez L; Cámara R; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Apr; 21(8):779-86. PubMed ID: 9603401
[TBL] [Abstract][Full Text] [Related]
12. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
[TBL] [Abstract][Full Text] [Related]
13. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM; Kakouros N; Qian W; Powell MG; Saini N; D'Sa S; Mackinnon S; Hoskin PJ; Goldstone AH; Linch DC
Br J Haematol; 2005 Aug; 130(3):363-72. PubMed ID: 16042685
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.
Lieskovsky YE; Donaldson SS; Torres MA; Wong RM; Amylon MD; Link MP; Agarwal R
J Clin Oncol; 2004 Nov; 22(22):4532-40. PubMed ID: 15542804
[TBL] [Abstract][Full Text] [Related]
15. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
Sureda A; Mataix R; Hernández-Navarro F; Jarque I; Lahuerta JJ; Tomás JF; Brunet S; Caballero D; Conde E; León A; Fernández MN; López A; Maldonado J; Bengoechea E; Callís M; Carrera D; García-Conde J; García-Laraña J; Moraleda JM; Morey M; Rifón J; Sierra J; Torres A; Domingo-Albós A
Bone Marrow Transplant; 1997 Aug; 20(4):283-8. PubMed ID: 9285542
[TBL] [Abstract][Full Text] [Related]
17. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
Burns LJ; Daniels KA; McGlave PB; Miller WJ; Ramsay NK; Kersey JH; Weisdorf DJ
Bone Marrow Transplant; 1995 Jul; 16(1):13-8. PubMed ID: 7581112
[TBL] [Abstract][Full Text] [Related]
20. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]